Breaking the Taboo Associated with Hemorrhoidal Disease
- Details
- Category: Bayer
![Bayer Bayer](/images/stories/logo/bayer.gif)
Nycomed well positioned in emerging markets
- Details
- Category: Nycomed
![Nycomed Nycomed](/images/stories/logo/nycomed.gif)
Roche Annual General Meeting: dividend raised by 10%
- Details
- Category: Roche
![Roche Roche](/images/stories/logo/roche.gif)
Nycomed's novel COPD therapy roflumilast receives FDA approval
- Details
- Category: Nycomed
![Nycomed Nycomed](/images/stories/logo/nycomed.gif)
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
- Details
- Category: Genzyme
![Genzyme Genzyme](/images/stories/logo/genzyme.gif)
Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab)
- Details
- Category: Amgen
![Amgen Amgen](/images/stories/logo/amgen.gif)
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
- Details
- Category: Bayer
![Bayer Bayer](/images/stories/logo/bayer.gif)
More Pharma News ...
- Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
- Sanofi Pasteur and International Vaccine Institute Partner against Dengue
- ONGLYZA™ US label update regarding use in renally impaired adults with type 2 diabetes
- Forest Laboratories to Acquire Clinical Data, Inc.
- Novartis gains positive CHMP opinion for Rasilamlo(TM)
- Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
- Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year